Asthma and Allergy News and Research

Medication Recall Alert: Puriton Eye Relief Drops Due to Non-Sterile Production Conditions

Kadesh Incorporation Issues Voluntary Nationwide Recall of Puriton Eye Relief Drops Due to Non-Sterile Production Conditions For Immediate Release November 7, 2018 Contact Consumers Recall Department contact@puriton.us Announcement Kadesh, Inc. of Garden Grove, CA is voluntarily recalling all lots of Puriton Eye Relief Drops, 0.5 oz. (15ml) bottle, UPC 7 36972 1679 0, to the consumer level. During a recent FDA inspection, investigators observed that ophthalmic drugs, which are required to be...

AAFA Study Shows Surprising Rate and Severity of Atopic Dermatitis in Adults

The Asthma and Allergy Foundation of America (AAFA) led a research study called Atopic Dermatitis in America . The purpose of this study is to shed light on the number of adults who deal with this frustrating skin condition. This week, AAFA has released early findings from the report. One surprising find from the study was the number of adults with AD who say it is moderate to severe. As many as 40% of the people surveyed said they had moderate-to-severe AD. Through this study, we hope to...

FDA Grants Breakthrough Therapy Designation for Tezepelumab for Severe Asthma

AstraZeneca and its partner Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.

Aetna Decides FeNO Testing Is Medically Necessary for Its Members With Asthma

Circassia Pharmaceuticals, Inc., a specialty pharmaceutical company focused on respiratory disease, is pleased to announce that Aetna, one of the largest health insurance companies in the United States, has updated its Exhaled Breath Tests Clinical Policy to include the measurement of exhaled nitric oxide as “medically necessary” for the evaluation of asthma and for monitoring the response to long-term control therapy.

Walgreens Locations Will Now Carry AUVI-Q Epinephrine Auto-Injectors

Walgreens and kaléo, a privately-held pharmaceutical company, are working together to improve access to epinephrine auto-injectors by making kaléo’s AUVI-Q® 0.15 mg and 0.3 mg available through Walgreens locations nationwide. This comes in an effort to help thousands of Americans with their epinephrine needs during the back to school season, as supply issues have been reported to the U.S. Food and Drug Administration (FDA) by other manufacturers.

Asthma Medication Recall Alert: Montelukast Tablets From Camber Pharmaceuticals for Incorrect Drug in Bottle

The U.S. Food and Drug Administration is warning consumers and health care professionals about a voluntary recall of one lot of Montelukast Sodium Tablets – lot number MON17384, expiration 12/31/2019 – by Camber Pharmaceuticals, Inc., Piscataway, N.J. Sealed bottles labeled as montelukast sodium tablets, 10 milligram, 30-count bottle from Camber were found to instead contain 90 tablets of Losartan Potassium Tablets, 50 mg.

FDA Approves First Generic Competitor of EpiPen Epinephrine Auto-Injector

The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds. Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths.

Study Shows Anti-Viral Medicine Reduces Flu Symptoms in People With High-Risk Conditions, Like Asthma

Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications from the flu met the study’s primary objective, and showed superior efficacy in the primary endpoint of time to improvement of influenza symptoms versus placebo.

×
×
×
×